The Continuing Education (CE) courses provide excellent lectures
to participants at Annual Meetings and SOT makes some of the course presentations
available to a wider audience. Outstanding speakers have been identified based upon course evaluations, and these selected
speakers have agreed to participate in the SOT CE Speaker Bureau. Any
Regional Chapter may request a presenter from the list below for chapter
meetings, and SOT will provide funding to cover the speaker's costs through
Funding for
Regional Chapter Activities and Speakers. Limited funds are available
and these will be allocated as requests are received, so it is important
Steven A. Belinsky
Lovelace Respiratory Research Institute
Albequerque, NM |
Epigenome Profiling: Mapping Epigenetic Alterations in Health and Disease
(2010, Salt Lake City) |
Dr. Belinsky has worked in the field of tobacco carcinogenesis for >20 years and is internationally recognized for his work in lung cancer and translational studies for early detection of lung cancer. His research is currently focused on controlling lung cancer through the identification of gene targets and pathways that are disrupted during the development of this disease. |
Kim Boekelheide, MD, Ph.D.
Brown University
Pathology & Laboratory Medicine
Providence, RI |
Male Reproductive System: Anatomy, Physiology, and Endocrine Regulation
(2009, Baltimore) |
Endocrine disruptor effects (phthalates, bisphenol A);
Future of Toxicity Testing |
Garry Buettner, Ph.D.
University of Iowa
Free Radical Research Institute
Iowa City, IA |
The Basics of Free Radicals: Their Formation, Chemical Properties, Fate, and Resulting Biochemical and Biological Consequences
(2009, Baltimore) |
Free Radical Chemistry and Biology; Quantitative Redox Biology; Redox Biology in the treatment of cancer; the role of superoxide and H2O2 in the basic biology of cells and tissues. |
James Bus, Ph.D., DABT, ATS
Dow Chemical Company
Toxicology Research Laboratory
Midland, MI |
Why is an Understanding of Toxicokinetics Important?
(2009, Baltimore) |
Importance of using pharmacokinetic data generated in animal toxicology studies to improve relevance of these studies to real-world human exposure assessments, facilitate interpretation of human biomonitoring studies, and refine environmental chemical risk assessments. |
Jeanine Bussiere, Ph.D., DABT
Amgen Inc.
Dept. of Toxicology
Thousand Oaks, CA |
How Similar is Similar: Understanding the Impact of Homologous or Surrogate Protein Develoment
(2009, Baltimore) |
Immunotoxicology, Biotherapeutics Safety Assessment, Primate Reproductive Toxicity |
Deborah Cory-Slechta, Ph.D.
University of Rochester Medical Center
Dept. of Environmental Medicine
Rochester, NY |
Biomarkers of Metal Intoxication: How Predictive Are Exposures of Adverse Effects?
(2009, Baltimore) |
Neurotoxicology, behavioral toxicology, developmental neurotoxicology, neurodegenerative disease, cumulative risk assessment |
James A. Dykens, Ph.D.
Pfizer Global Research & Development,
Sandwich, UK |
Mitochondrial Function and Dysfunction in Disease and Drug-Induced Toxicity
(2010, Salt Lake City) |
|
Susan G. Emeigh Hart, VMD, Ph.D., DACVP, DABT, ERT
Auxilium Pharmaceuticals, Inc.
Malvern, PA |
The Kidney: Anatomic and Physiologic Features of Mechanistic Relevance
(2010, Salt Lake City) |
Renal and ocular anatomy and physiology (normal and pathologic), renal and ocular toxicology, anatomic and clinical pathology of laboratory animals, extracellular matrix biology and pathophysiology, drug development (small molecule and biologics, pre-IND to NDA/BLA) |
Nancy Everds, DAVM, DACVP
Amgen Inc.
Pathology Department
Seattle, WA |
Stress and Clinical Pathology
(2009, Baltimore) |
Clinical Pathology on Toxicology Studies; effects of preanalytical procedures on clinical pathology parameters; rodent clinpath |
Shawn M. Heidel, DVM, Ph.D.
Eli Lilly & Company
Indianapolis, IN |
Principles for Development of Proteins
(2010, Salt Lake City) |
Safety assessment of biopharmaceuticals, comparability testing, biosimilars, and regulatory toxicology. |
Christopher Horvath, DVM, DACVP
Taligen Therapeutics,
Cambridge, MA |
Cytokine Storms: It’s Not Nice to Fool With Mother Nature
(2010, Salt Lake City) |
Translational (preclinical to clinical) development of biologics, FIH dose selection and justification, immunogenicity effects, comparative immunopathology, establishing NOAELs |
Randy L. Jirtle, Ph.D.
Duke University Medical Center,
Durham, NC |
Environmental Epigenomics and Disease Susceptibility
(2010, Salt Lake City) |
Role of epigenetics and genomic imprinting in human health and toxicological risk assessment. |
Ian Kimber, Ph.D.
University of Manchester
Michael Smith Building
Manchester, United Kingdom |
An Introduction to Immunology: Fundamental and Clinical Aspects
(2009, Baltimore) |
Immunotoxicology in general, Immunology, Cutaneous immunology, Dendritic cells, Chemical allergy, Food allergy, Alternative test methods |
Daniel M. Lapadula, Ph.D., DABT
Novartis Pharmaceuticals Corporation,
East Hanover, NJ |
Preclinical Development of Oncology Therapeutics: An Industry Perspective
(2010, Salt Lake City) |
Accelerating drug development of anticancer drugs and impact of new regulatory guidance. |
Kevin T. Morgan, Ph.D.
Safoni-Aventis
Research Triangle Park, NC |
From the Land of Classical Mammalian Toxicology and Pathology to the Land of In Vitro, Molecular, Genomics, and Other Tools
(2010, Salt Lake City) |
- The meaning of life.
- Biology in general, especially with respect to dynamics as it relates to understanding 'omics' data.
- Normal physiology with special reference to intermediary metabolism and bioenergetics.
- Mechanisms of disease.
- The application of mathematical modeling to Biology.
|
Kent E. Pinkerton, Ph.D.
University of California
Davis, CA |
Comparative Anatomy of Mammalian Respiratory Systems
(2010, Salt Lake City) |
The health impacts of inhaled gases and particles on the respiratory system. The effects of environmental tobacco smoke and airborne particulates on perinatal development of the respiratory,immune and neural systems. Adverse and beneficial effects of inhaled engineered nanomaterials. |
Paul S. Price
The Dow Chemical Company
Midland, MI |
New Tools—How Do They Affect the Bottom Line?
(2010, Salt Lake City) |
Characterizing risks from mixtures; Understanding how advances in toxicology can help improve risk assessments; and Using probabilistic techniques to improve risk assessment.
|
Jeffrey S. Tepper, Ph.D., DABT
Tepper Nonclinical Consulting,
San Carlos, CA |
Interpretation and Limitations in the Assessment of Lung Function in Laboratory Mammals
(2010, Salt Lake City) |
Biopharmaceutical pharmacology and regulatory toxicology. Particular expertise in inhalation toxicology and animal models of respiratory and immunological disease. |
Mark Vezina
Charles River Laboratories,
Montreal, QC, Canada |
Comparative Ocular Anatomy and Physiology in Laboratory Animals
(2010, Salt Lake City) |
Ocular safety evaluations, ocular tissue distribution, retinal electrophysiology, neuroprotection and animal models of ocular disease |
Yvonne Will, Ph.D.
Pfizer Global Research & Development
Groton, CT |
In Vitro Approaches to Assess Mitochondrial Toxicity and Mitochondria-Mediated Drug Toxicity: Advantages and Limitations
(2010, Salt Lake City) |
Mitochondrial toxicity, HTS applicable safety screens, liver injury, cardio toxicity, cell based assays |
